Bayer stock heads into the open after a 2.4% Xetra gain

At the close on September 14, 2026, Bayer stock finished the Xetra session higher, with late trading around 49.33 euros and gains of roughly 2.4 percent versus the prior day. The shares outperformed a weaker DAX 40, which closed down about 0.6 percent that day.

Bayer stock closed the last completed Xetra session on September 14, 2026 with gains of about 2.4 percent versus the prior close, ending late trading around 49.33 euros in Frankfurt per market data reported that evening. Compared with the DAX 40, which finished the same session roughly 0.6 percent lower near 25,415 points, the shares outperformed the broader German blue-chip index on that date.

September 14, 2026 in numbers

Bayer AG (ISIN DE000BAY0017) saw its shares trade in the upper 49-euro range on Xetra on September 14, 2026, with intraday levels such as 49.14 euros and a reported day high around 49.28 euros in morning trading as the stock advanced on the day. Per Xetra closing data cited in German market reports, the late-session indication around 49.33 euros represented an increase of roughly 2.4 percent from a prior close slightly below 48.20 euros, placing the stock among the notable gainers in the DAX 40 while the index itself slipped about 0.6 percent to close near 25,415 points.

As Investing.com reported on September 14, 2026, Bayer shares were up about 2.41 percent late in the session, trading near 49.33 euros while the DAX 40 closed lower, highlighting the stock's relative strength against a softer German market backdrop that day. Intraday commentaries from portals such as finanzen.ch and Trading-Treff pointed to the stock trading around 49.14 to 49.32 euros in morning and midday dealings, with day gains in the low- to mid-single-digit percent range and volumes in line with typical Xetra activity, leaving the price still below longer-term analyst target levels but clearly above the prior close.

Legal focus and today's context

Beyond the pure price action, the recent advance in Bayer shares has been closely tied to legal developments around the company's proposed settlement of US Roundup litigation. As Ad-hoc-news noted on September 14, 2026, investors were positioning ahead of a key US court hearing on a proposed 7,250.0 million USD Roundup settlement, with Bayer stock up between roughly 2.5 and 3.9 percent intraday as Xetra quotes reflected the legal focus and hopes for more clarity on future litigation risks. Commentary from trading portals such as Trading-Treff on the same date described the shares around 49.24 euros with a day gain of about 2.2 percent, reinforcing that expectations around the court process and the potential settlement framework were an important backdrop to the stock's move in the last session.

Today, September 15, 2026, the Xetra market is open as usual, and Bayer stock heads into the new session with the prior close and recent legal headlines likely remaining in focus for investors awaiting further signals from the US proceedings. While no specific Bayer quarterly earnings release or capital markets event is scheduled for today in publicly cited calendars, the outcome and timing of the Roundup-related hearing in the United States, as flagged by legal and market reports, continue to shape sentiment toward the shares. In addition, the broader DAX 40 performance and any new developments in interest-rate expectations or macroeconomic data that affect German cyclicals and healthcare names may provide additional context for how Bayer stock trades once the new Xetra session is underway.